Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (16)
  • Open Access

    ARTICLE

    Predicting 3D Radiotherapy Dose-Volume Based on Deep Learning

    Do Nang Toan1,*, Lam Thanh Hien2, Ha Manh Toan1, Nguyen Trong Vinh2, Pham Trung Hieu1

    Intelligent Automation & Soft Computing, Vol.39, No.2, pp. 319-335, 2024, DOI:10.32604/iasc.2024.046925 - 21 May 2024

    Abstract Cancer is one of the most dangerous diseases with high mortality. One of the principal treatments is radiotherapy by using radiation beams to destroy cancer cells and this workflow requires a lot of experience and skill from doctors and technicians. In our study, we focused on the 3D dose prediction problem in radiotherapy by applying the deep-learning approach to computed tomography (CT) images of cancer patients. Medical image data has more complex characteristics than normal image data, and this research aims to explore the effectiveness of data preprocessing and augmentation in the context of the… More >

  • Open Access

    ARTICLE

    Targeted anti-tumor synergistic effects of Myc decoy oligodeoxynucleotides-loaded selenium nanostructure combined with chemoradiotherapy on LNCaP prostate cancer cells

    ROGHAYEH GHORBANI1, MAHMOUD GHARBAVI2, ALI SHARAFI3,4, ELHAM RISMANI5, HAMED REZAEEJAM6, YOUSEF MORTAZAVI1,*, BEHROOZ JOHARI3,*

    Oncology Research, Vol.32, No.1, pp. 101-125, 2024, DOI:10.32604/or.2023.044741 - 15 November 2023

    Abstract In the present study, we investigated the synergistic effects of targeted methotrexate-selenium nanostructure containing Myc decoy oligodeoxynucleotides along with X-irradiation exposure as a combination therapy on LNCaP prostate cancer cells. Myc decoy ODNs were designed based on the promoter of Bcl-2 gene and analyzed by molecular docking and molecular dynamics assays. ODNs were loaded on the synthesized Se@BSA@Chi-MTX nanostructure. The physicochemical characteristics of nanostructures were determined by FTIR, DLS, UV-vis, TEM, EDX, in vitro release, and hemolysis tests. Subsequently, the cytotoxicity properties of them with and without X-irradiation were investigated by uptake, MTT, cell cycle, apoptosis, and… More > Graphic Abstract

    Targeted anti-tumor synergistic effects of Myc decoy oligodeoxynucleotides-loaded selenium nanostructure combined with chemoradiotherapy on LNCaP prostate cancer cells

  • Open Access

    ARTICLE

    A Novel Unsupervised MRI Synthetic CT Image Generation Framework with Registration Network

    Liwei Deng1, Henan Sun1, Jing Wang2, Sijuan Huang3, Xin Yang3,*

    CMC-Computers, Materials & Continua, Vol.77, No.2, pp. 2271-2287, 2023, DOI:10.32604/cmc.2023.039062 - 29 November 2023

    Abstract In recent years, radiotherapy based only on Magnetic Resonance (MR) images has become a hot spot for radiotherapy planning research in the current medical field. However, functional computed tomography (CT) is still needed for dose calculation in the clinic. Recent deep-learning approaches to synthesized CT images from MR images have raised much research interest, making radiotherapy based only on MR images possible. In this paper, we proposed a novel unsupervised image synthesis framework with registration networks. This paper aims to enforce the constraints between the reconstructed image and the input image by registering the reconstructed… More >

  • Open Access

    ARTICLE

    Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study

    SUKRAN SENYUREK1, SEZER SAGLAM2,*, ESRA KAYTAN SAGLAM3, HAKAN YANAR4, KAAN GOK4, DIDEM TASTEKIN5, CANAN KOKSAL AKBAS6, NERGIZ DAGOGLU SAKIN3, GULBIZ DAGOGLU KARTAL7, EMRE BALIK8, METIN KESKIN4, YASEMIN SANLI9, MINE GULLUOGLU10, ZULEYHA AKGUN11

    Oncology Research, Vol.31, No.5, pp. 689-696, 2023, DOI:10.32604/or.2023.030351 - 21 July 2023

    Abstract Radiation therapy (RT) is typically applied using one of two standard approaches for preoperative treatment of resectable locally advanced rectal cancer (LARC): short-course RT (SC-RT) alone or long-course RT (LC-RT) with concurrent fluorouracil (5-FU) chemotherapy. The Phase II single-arm KROG 11-02 study using intermediate-course (IC) (33 Gy (Gray)/10 fr (fraction) with concurrent capecitabine) preoperative chemoradiotherapy (CRT) demonstrated a pathologically complete response rate and a sphincter-sparing rate that were close to those of LC-CRT. The current trial aim to compare the pathological/oncological outcomes, toxicity, and quality of life results of LC-CRT and IC-CRT in cases of… More >

  • Open Access

    ARTICLE

    Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study

    OZAN CEM GULER1,*, EZGI OYMAK2, GOZDE YAZICI3, OZLEM OZKAYA AKAGUNDUZ4, OGUZ CETINAYAK5, PETEK ERPOLAT6, ATIL AKSOY7, MURSEL DUZOVA8, BERNA AKKUS YILDIRIM9, MERAL KURT10, EMINE CANYILMAZ11, GULER YAVAS12, SERAP AKYUREK13, DIDEM COLPAN OKSUZ14, ESRA KAYTAN SAGLAM15, OMUR KARAKOYUN CELIK16, ENIS OZYAR17, MUSTAFA CENGIZ3, CEM ONAL1,2,12

    Oncology Research, Vol.31, No.3, pp. 299-306, 2023, DOI:10.32604/or.2023.028840 - 22 May 2023

    Abstract The aim of this study was to examine the prognostic factors and treatment outcomes of cervical esophageal carcinoma (CEC) patients who underwent definitive chemoradiotherapy (CRT). The clinical data of 175 biopsy-confirmed CEC patients treated with definitive CRT between April 2005 and September 2021 were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local recurrence-free survival (LRFS) were assessed in uni- and multivariable analyses. The median age of the entire cohort was 56 years (range: 26–87 years). All patients received definitive radiotherapy with a median total dose of 60 Gy, and… More >

  • Open Access

    REVIEW

    Treatment options in stage I seminoma

    UROS BUMBASIREVIC1,2,*, MARKO ZIVKOVIC1, MILOS PETROVIC1, VESNA CORIC2,3, NIKOLA LISICIC1, NEBOJSA BOJANIC1,2

    Oncology Research, Vol.30, No.3, pp. 117-128, 2022, DOI:10.32604/or.2022.027511 - 12 January 2023

    Abstract Seminomas are most commonly diagnosed in clinical stage I (CSI). After orchiectomy, approximately 15% of patients in this stage have subclinical metastases. Adjuvant radiotherapy (ART) delivered to the retroperitoneum and ipsilateral pelvic lymph nodes has been the mainstay of treatment for many years. Although highly efficient, with long-term cancer-specific survival (CSS) rates approaching almost 100%, ART is associated with considerable long-term consequences, particularly cardiovascular toxicity and increased risk of secondary malignancies (SMN). Therefore, active surveillance (AS) and adjuvant chemotherapy (ACT) were developed as alternative treatment options. While AS prevents patient overtreatment, it is associated with… More >

  • Open Access

    ARTICLE

    RPA3 is transcriptionally activated by YY1 and its depletion enhances radiosensitivity of triple-negative and HER2-positive breast cancer

    YANFEI LI1, LULU DAI2, KE CAI2, YINGKUI SONG2, XIQING LIU3,*

    BIOCELL, Vol.45, No.3, pp. 685-694, 2021, DOI:10.32604/biocell.2021.013612 - 03 March 2021

    Abstract RPA3 (Replication Protein A3) (14 kD) is a part of the canonical heterotrimeric replication protein A complex (RPA/RP-A). This study aimed to explore the functional role of RPA3 and the mechanisms of its dysregulation in breast cancer. Data from the Cancer Genome Atlas (TCGA)-breast cancer patients and GSE75688 were utilized for gene expression and survival analysis. Breast cancer cell lines MDA-MB-231 and SK-BR-3 were used for in-vitro cell studies. Clonogenic assay and immunofluorescent staining of γ-H2AX were performed to examine radiation-induced cytotoxicity. Systemic correlation analysis was performed to identify potential transcription factors (TFs) regulating RPA3… More >

  • Open Access

    ARTICLE

    Changes in DNA Damage Repair Gene Expression and Cell Cycle Gene Expression Do Not Explain Radioresistance in Tamoxifen-Resistant Breast Cancer

    Annemarie E. M. Post*†, Johan Bussink*, Fred C. G. J. Sweep, Paul N. Span*

    Oncology Research, Vol.28, No.1, pp. 33-40, 2020, DOI:10.3727/096504019X15555794826018

    Abstract Tamoxifen-induced radioresistance, reported in vitro, might pose a problem for patients who receive neoadjuvant tamoxifen treatment and subsequently receive radiotherapy after surgery. Previous studies suggested that DNA damage repair or cell cycle genes are involved, and could therefore be targeted to preclude the occurrence of cross-resistance. We aimed to characterize the observed cross-resistance by investigating gene expression of DNA damage repair genes and cell cycle genes in estrogen receptor-positive MCF-7 breast cancer cells that were cultured to tamoxifen resistance. RNA sequencing was performed, and expression of genes characteristic for several DNA damage repair pathways was… More >

  • Open Access

    ARTICLE

    Endostar, an Antiangiogenesis Inhibitor, Combined With Chemoradiotherapy for Locally Advanced Cervical Cancer

    Heming Lu*†1, Yuying Wu‡1, Xu Liu, Huixian Huang, Hailan Jiang, Chaohua Zhu, Yuping Man§, Zhaohong Chen, Xianfeng Long, Qiang Pang, Luxing Peng, Xianglong Li, Junzhao Gu, Shan Deng, Ligang Xing*

    Oncology Research, Vol.28, No.9, pp. 929-944, 2020, DOI:10.3727/096504021X16318716607908

    Abstract This phase II randomized clinical trial aimed to assess the efficacy and toxicity of Endostar, an antiangiogenesis inhibitor, combined with concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC). Patients with LACC were randomly assigned to either CCRT plus Endostar (CCRT+E arm) or CCRT alone (CCRT arm). All patients received pelvic intensity-modulated radiation therapy (IMRT) and brachytherapy. Weekly cisplatin was administered concurrently with IMRT. Patients in the CCRT+E arm also received concurrent Endostar every 3 weeks for two cycles. The primary endpoint was progression-free survival (PFS) and acute toxicities. The exploratory endpoint was the impact… More >

  • Open Access

    ARTICLE

    A Panel of Tumor Biomarkers to Predict Complete Pathological Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer

    Chiara Dalle Fratte*, Silvia Mezzalira*, Jerry Polesel, Elena De Mattia*, Antonio Palumbo, Angela Buonadonna§, Elisa Palazzari, Antonino De Paoli, Claudio Belluco#, Vincenzo Canzonieri‡** , Giuseppe Toffoli*, Erika Cecchin*

    Oncology Research, Vol.28, No.9, pp. 847-855, 2020, DOI:10.3727/096504021X16232280278813

    Abstract Pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients is related to a favorable prognosis. The identification of early biomarkers predictive of pathological complete response would help optimize the multimodality management of the patients. A panel of 11 tumor-related proteins was investigated by immunohistochemistry in the pretreatment biopsy of a group of locally advanced rectal cancer patients to identify early biomarkers of pathological complete response to neoadjuvant chemoradiotherapy. A mono-institutional retrospective cohort of 95 stage II/III locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy and surgery was selected based on clinical–pathological… More >

Displaying 1-10 on page 1 of 16. Per Page